AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...
April 8 (Reuters) - AbbVie has filed a lawsuit against the U.S. government, seeking clearer guidance on patients eligible for ...
AbbVie has filed a legal challenge seeking to narrow and clarify who counts as an "eligible patient" under the federal 340B ...
A federal court has struck down a 12-year-old Health Resources and Services Administration policy that restricted how certain 340B hospitals could make initial drug purchases, finding that the agency ...
Tuesday’s bill gives powers to the Attorney General’s Office to further enforce state law that prohibits manufacturers from ...
A federal judge has, at least temporarily, nixed a longstanding restriction on whether some 340B hospitals could use group ...
Humira and Botox maker AbbVie is suing the Trump administration to get a clearer definition of who counts as an eligible ...
Hospital groups and 340B advocates counter that the discounts are a financial lifeline that helps fund community health ...
Drug companies want to end it. This is not a partisan issue. It is a math issue. And for the patients and communities we serve, it is a survival issue.
4dOpinion
We owe it to breast cancer patients to fix the 340B drug program (Guest Opinion by Maimah Karmo)
Advocate calls for 340B reforms to ensure drug savings reach vulnerable breast cancer patients in need, like Ravan Patrick.
"The savings from this program support pharmacy services, emergency care, behavioral health, and care for patients who are ...
Pharmaceutical companies are spending hundreds of millions lobbying elected officials to try and persuade them to gut the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results